Article

Researchers Create Dust Mite Vaccine

Author(s):

Dust mites are widely responsible for allergic irritation and breathing difficulties, but researchers from the University of Iowa researchers indicated a vaccine may be within reach.

Attracted to skin cells, dust mites are widely responsible for allergic irritation and breathing difficulties. Fortunately, findings from University of Iowa (UI) researchers indicated a vaccine may be within reach.

The effects of dust mites can vary from allergic irritation to lung damage. Previous studies have shown that dust mites can be found in 85% of homes and cause breathing problems in 45% of asthmatics.

Currently, there is no long-term cure, with affected asthmatics using inhalers as a short-term remedy.

A July 1 issue of The American Association of Pharmaceutical Scientists Journal announced the discovery of cytosine-phosphate-guanine motifs (CpG) located within poly(lactic-co-glycolic acid) (PLGA) particles as a possible vaccination option. CpG, an immunity booster, has been used successfully in cancer vaccinations, according to a statement from UI .

To test its effectiveness, mice were given a CpG-antigen combination and exposed to dust mites for a 10-day period. Upon euthanization, the researchers measured the mice’s leukocyte accumulation in bronchoalveolar lavage (BAL) fluids, antibody profiles, and airway hyperresponsiveness.

The authors reported that PLGA particles used for vaccination significantly reduced inflammatory responses to Dermatophagoides pteronyssinus-2 (der p2) antigen.

“This study shows that the size of PLGA particles used for vaccination plays a major role in the prevention of house dust mite-induced allergy and that incorporation of CpG into the PLGA particles preferentially develops a Th1-type immune response,” the authors wrote.

The university further reported that in animals the treatment resulted in an 83% decrease in lung inflammation after dust mite exposure. The 300 nanometer combination also achieved a 90% absorption rate.

“Our research explores a novel approach to treating mite allergy in which specially-encapsulated miniscule particles are administered with sequences of bacterial DNA that direct the immune system to suppress allergic immune responses," Peter Thorne, public health professor at the UI and a contributing author on the paper, said in a statement. "This work suggests a way forward to alleviate mite-induced asthma in allergy sufferers.”

Related Videos
Hope on the Horizon: 2 Food Allergy Breakthroughs in 2024
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
How to Manage Aspirin-Exacerbated Respiratory Disease
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
MeiLan Han, MD: Discussing Updates on Dupilumab, Ensifentrine in 2025 GOLD Report
Physician, Patient, and Partner Perspectives on AERD with Mitchell Grayson, MD, Rhonda Nelson, and Wayne Nelson
Monica Kraft, MD: Discussing Phase 3b Findings on Albuterol/Budesonide for Asthma
How Artificial Intelligence is Being Used in Lung Imaging, with Rachel Eddy, PhD
Developing Risk Assessment Tools for Viruses in School
© 2024 MJH Life Sciences

All rights reserved.